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Abstract   
Introduction: PPP2R5C is one of the regulatory B subunits of protein phosphatase 2A 
(PP2A), which is a tumor suppressor. PPP2R5C plays a critical role in cell proliferation, 
differentiation, and transformation. Considering these vital functions, we investigate the gene 
expression in Iranian patients with B-Acute Lymphoblastic Leukemia (B-ALL) and its 
association with clinical and laboratory finding. 
Materials and methods: In this case-control study, peripheral blood samples were collected 
from 60 B-ALL patients and 30 healthy controls. PPP2R5C expression levels were 
determined by Real-time PCR. After calculation of CT for target and control genes, we 
calculated ΔCT. Finally we compared the PPP2R5C expression levels in patients with control 
group. 
Results: Significantly higher expression of PPP2R5C was found in the B-ALL patients 
(2.15±2. 50) compared with control group. There was no correlation between PPP2R5C 
expression and clinical and laboratory findings and FAB (French-American-British) subtype 
of patients. 
Conclusion: we demonstrated PPP2R5C overexpression in B-ALL patients. Although there 
was no significant correlation between PPP2R5C expression, clinical and laboratory finding 
and also with FAB subtypes of patients.  
Keywords: B-Acute Lymphoblastic Leukemia, PPP2R5C, PP2A, Gene expression
Introduction  
Acute Lymphoblastic Leukemia (ALL) is 
a form of leukemia that is characterized by 
overproduction and subsequently bone 
marrow infiltration of lymphoblasts and 
other body organs involvement. Although 
it may be diagnosed at any age, it is the 
most common malignancy of infants and 
teenagers. In the current WHO 
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classification, two subtypes, B-ALL and 
T-ALL, are recognized; B-ALL comprises 
the great majority of cases (1). In many 
cases the cause of leukemia is ambiguous 
but mutations, deletions, chromosomal 
defects, up or down regulation of cellular 
signaling pathways as well as 
dysregulation of Epigenetic events can be 
causative factors of leukemia (2-4). The 
opposing function of phosphatases and 
kinases is a more important mechanism 
involved in regulation of different 
signaling pathways, so aberrations in 
regulatory proteins of these mechanisms 
may be from significant causes of 
leukemia (5). 
Protein phosphatase 2A (PP2A) is a 
Ser/Thr protein phosphatase with a 
heterotrimer structure. It has a catalytic 
subunit (C), a scaffold subunit (A) and 
several variable regulatory subunits (B). 
The regulatory subunits are four families 
which B56 family members consist of 
PPP2R5A, PPP2R5B, PPP2R5C, 
PPP2R5D, and PPP2R5E. Observations 
demonstrated that B56 family are more 
important in malignant transformation (6-
10), by its inducing effect on 
dephosphorylation of P53. PPP2R5C plays 
a vital role in cell proliferation, 
differentiation, and transformation (11-13). 
With regard to the critical functions of 
PPP2R5C we investigated the gene 
expression of this protein in Iranian 
patients with B-Acute Lymphoblastic 
Leukemia and its association with clinical 
and laboratory findings. 
Materials and methods  
This study was performed in the Research 
laboratory of molecular hematopathology 
of Ghaem Hospital in Mashhad, Iran. 60 
newly diagnosed and untreated patients 
with B-ALL and 30 individuals as control 
were enrolled into the study. All patients 
were categorized in FAB classification 
groups. At the beginning of study, 
informed consent was obtained from all 
groups. The clinical and laboratory 
parameter including lymphadenopathy, 
splenomegaly,hepatomegaly, demographic 
data, immunophenotyping results and 
other laboratory parameters, were retrieved 
from medical records of patients. 
Peripheral blood was collected from all 
patients in K2-EDTA containing vials. 
Ficoll gradient centrifugation was used to 
isolate mononuclear cells. The RNA was 
extracted using RNX plus kit according to 
the manufacturer’s instructions (Cinnagen, 
Tehran, Iran). Subsequently, cDNA 
synthesis was performed using primers of 
Random Hexamer. PPP2R5C gene 
expression analysis on patient’s samples 
and control group was done using real 
time-PCR method. Gene expression levels, 
were applied by SYBRGreen (TAKARA) 
and relative expression was calculated 
from 2-ΔΔCT method. PPP2R5C gene 
expression normalized against the internal 
gene, beta-2-microglobolin (β2M), by 
specific primers depicted in table 1.  
In order to ensure the specificity of the 
real-time PCR products, melting curves 
were plotted after each working run. For 
standard curve, 0.1, 0.01, and 0.001 
dilutions were prepared from primers of 
PPP2R5C and β2M. Amplification curves 
were plotted following performing of the 
test. The results of PPP2R5C gene 
expression levels in patients were 
compared with that of the control group. 
Data were analyzed by SPSS, version19. 
The Kolmogorov–Smirnov test and Chi-
Square independent sample t-test were 
used in case needed. P-value less than 0.05 
were considered as significant.  
Results  
We studied 60 patients diagnosed with B- 
ALL and 30 individuals as control group. 
The patients group included 30(50%) 
males, 30(50%) females and the control 
group was made of 15(50%) males and 
15(50%) females. Mean ± SD age of 
patients and control group were 13±14 
years (range: 1-65 years) and 16±7 years 
(range: 3-42 years), respectively. FAB 
classification of patients include 45(75%), 
ALL-L1 and 15(25%) ALL-L2 
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respectively. WBC counts, platelet counts 
and hemoglobin concentration in patients 
and the correlation between FAB 
classification and gene expression level in 
patients are shown in table 2. There was no 
significant relationship between the 
expressions level of PPP2R5C and these 
parameters. The included clinical features 
were hepatomegaly (44%), splenomegaly 
(66%), lymphadenopathy (42%) and 
petechia-purpura (24%). There was no 
significant association between the 
expressions level 3of PPP2R5C and 
clinical presentations (Table 3). 
We examined the genetic abnormalities 
such as t (12; 21), t (1; 19) and t (9; 22), 
there was no significant correlation 
between the expressions level of PPP2R5C 
and genetic abnormalities (Table 4). 
Significantly higher expression of 
PPP2R5C was found in the patients (2.15 
±2.50) compared with healthy controls. 
The number of patients that had 
upregulated expression of PPP2R5C was 
70% (42 out of 60). There was no 
significant relationships between the 
expressions level of PPP2R5C and 
different FAB subtypes (P value > 0.05). 
  
Table 1. Primer sequence for two genes (PPP2R5C and β2M). 
Gene Primer  Sequence (5’ to 3’) 
PPP2R5C Forward  GTAATAAAGCGGGCAG-CAGG 
 Reverse  CAAAGTCAAAGAGACGCAACA 
β2M Forward  CAGCAAGGACTGGTCTTTCTAT 
 Reverse  CAGCAAGGACTGGTCTTTCTAT 
 
Table 2. Characteristics and laboratory findings of the patients with B-ALL. 
Characteristics Fab subtype  PPP2R5C Expression Level  
L1 L2  Up Regulate Down Regulate P value 
Number of Patients, (%) 45(75) 15(25)  42(70) 18(30)  
Male 22 8  20 11 
Female 23 7  22 7 
WBC count (109/L, 
median) 
51.05 62.16  57.55 49.14 0.641 
Platelet count (109/L, 
median) 
79.86 11.84  73.07 55.31 0.192 
Hb, g/dl (median) 6.5 7.2  6.42 7.08 0.383 
 
Table 3. Differences in expression level of PPP2R5C in patients with different clinical presentations. 
Clinical 
presentations 
Lymphadenopathy Splenomegaly Hepatomegaly Petechiae-Purpura 
Positive Negative Positive Negative Positive Negative Positive Negative 
PPP2R5C level 3.06 1.50 2.10 2.25 2.52 1.93 3.47 1.74 
P value 0.227 0.757 0.418 0.118 
Table 4. Differences in expression level of PPP2R5C in B- ALL patients with different genetic abnormalities. 
Translocation 
 
t(12;21) t(9;22) t(1;19) 
Positive Negative Positive Negative Positive Negative 
Number 11 49 17 43 7 53 
PPP2R5C level 2.476 2.069 2.547 1.958 2.683 2.073 
P value 0.639 0.488 0.550 
Discussion 
PPP2R5C is one of the regulatory subunits 
of protein phosphatase 2A (PP2A) which 
is a key cellular serine/threonine 
phosphatase affecting the phosphorylation 
site of many proteins (9). PP2A is one of 
the Ras-Raf signaling pathway regulators. 
The normal function of Akt is tightly 
modulated by phosphorylation events (14). 
The function of PP2A in Wnt/β-catenin 
signaling is similar to its role in MAPK 
pathway (15). In response to γ radiation 
PP2A dephosphorylates p53 hence 
affecting apoptosis in mammalian cells 
[16]. PP2A also plays a prominent role in 
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controlling the accumulation of the 
protoncoprotein, c-Myc (17).  
Recent studies have demonstrated 
decreased expression of PPP2R5C in B-
CLL, so it was concluded to be a marker 
of progressive disease in B-CLL. 
Researchers have compared expression of 
PPP2R5C in stable and progressive B-CLL 
without a control group (18). Another 
study, demonstrated that overexpression of 
PPP2R5C gene in ALL patients compared 
with control group (19). Two different 
mutations in lung cancer and intestinal 
cancer can disrupt B56γ -P53 interaction 
(12, 20). 
It has been showed that PPP2R5C 
suppression by RNAi can inhibit the 
proliferation of the Molt4 and Jourkat T 
cells (21). It also has been showed that the 
proliferation of the PPP2R5C–siRNA –
treated CML cell line was decreased in 
K562 Cell line (22). In our study 
significantly higher expression of 
PPP2R5C was found in Iranian patients 
with the B-ALL. We studied more patients 
than previous studies to confirm 
overexpression of PPP2R5C and also 
examined the relation of the PPP2R5C 
expression with clinical and laboratory 
findings that there was no significant 
relationship. Additionally, we also 
examined expression level of PPP2R5C 
among FAB subtypes of B-ALL (L1, L2) 
that there was no significant difference in 
expression level between them. In regard 
with the importance of PP2A in cancer, as 
demonstrated in several studies, expression 
pattern of PPP2R5C might be a critical 
finding in ALL patients. Definitive results 
for proven the upregulation of PPP2R5C 
in B-ALL patients particularly relation of 
the expression level of PPP2R5C with 
clinical and laboratory findings could be 
demonstrated by larger number of samples 
studied.  
Conclusion  
The present study revealed PPP2R5C 
overexpression in B-ALL patients. 
Although there was no significant relation 
between PPP2R5C expression clinical and 
laboratory finding and also with FAB 
subtypes of patients. 
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